Acorda Therapeutics, Inc. (NASDAQ:ACOR)

CAPS Rating: 4 out of 5

A commercial-stage biopharmaceutical company dedicated to the identification, development & commercialization of novel therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the CNS.


Player Avatar genedom (98.11) Submitted: 9/12/2013 3:07:59 AM : Outperform Start Price: $37.19 ACOR Score: -14.24

Short term momentum

Featured Broker Partners